Johnson & Johnson stock: J&J plans December 8 Enterprise Business Review

Published on 10/20/2026 at 17:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Full-year guidance is USD 101.20 billion for 2026. Johnson & Johnson stock costs EUR 230.95 on October 20, 2026, 0.04 percent above Xetra close.

December review and guidance

Johnson & Johnson plans its Enterprise Business Review for December 8, 2026.
Full-year reported sales guidance has a USD 101.20 billion midpoint for 2026.
Johnson & Johnson stock costs EUR 230.95 at Lang & Schwarz on October 20, 2026 at 5:32 p.m. CEST, 0.04 percent above the Xetra close of October 20, 2026.

Pop art comic book illustration of a large beige adhesive bandage roll centered on a halftone dot background in cyan and magenta, bold black comic outlines, yellow starburst and red lightning bolt elements radiating outward, flat primary colors of red blu — Johnson Consumer Health im Pop Art Stil, US4781601046 Pflasterrolle mit Halftone und Comic Outlines, Illustration mit AI erstellt.

Johnson & Johnson (ISIN US4781601046) plans an Enterprise Business Review for December 8, 2026, where management will discuss its 2027 outlook and development pipeline, according to Johnson & Johnson in remarks dated October 13, 2026. The stock was trading at EUR 230.95 at Lang & Schwarz on October 20, 2026 at 5:32 p.m. CEST, 0.04 percent above the Xetra close of October 20, 2026 at EUR 230.85.

Guidance points to USD 101.20 billion

The company set full-year 2026 reported sales guidance at USD 101.00 billion to USD 101.40 billion, with a USD 101.20 billion midpoint. The midpoint compares with USD 101.10 billion in the July 29, 2026 update, an increase of USD 100.00 million, according to Johnson & Johnson.

The same release set adjusted earnings per share guidance at USD 11.05 to USD 11.15, with a USD 11.10 midpoint. That midpoint is 2.90 percent above the USD 11.04 midpoint published on July 29, 2026, while the company said the range reflects special items and acquisition-related effects.

Stock sits below its yearly high

Johnson & Johnson's primary listing is on the NYSE under ticker JNJ. The USD 259.33 NYSE price at 11:34 a.m. ET on October 20, 2026 sits within the USD 184.66 to USD 281.07 52-week range. The current level is 7.73 percent below the high and 40.42 percent above the low, while the stock's year-to-date gain was 24.70 percent on October 15, 2026, according to Investing.com.

Valuation and the next date

Johnson & Johnson had a market capitalization of USD 625.0 billion and a price-to-earnings ratio of 39.33 as of October 20, 2026. Bernstein raised its target from USD 261.00 to USD 270.00 on October 15, 2026, leaving the target 4.12 percent above the USD 259.33 NYSE price, according to Investing.com. The December 8 Enterprise Business Review is the next dated corporate event identified in management's October 13 remarks.

Price and investor perspective

Johnson & Johnson combines a USD 625.0 billion market value with a 2.00 percent dividend yield and a 39.33 price-to-earnings ratio. The valuation therefore sits alongside a raised sales outlook, while the 52-week gap leaves the stock below its USD 281.07 high.

The further course of trading is shown by the continuously updated real-time quote of Johnson & Johnson stock.